The PAX8/PPARγ fusion oncogene as a potential therapeutic target in follicular thyroid carcinoma

Bryan McIver, S. K G Grebe, Norman L. Eberhardt

Research output: Contribution to journalArticle

42 Citations (Scopus)

Abstract

Follicular thyroid carcinoma (FTC) accounts for approximately 20% of all thyroid cancers, and up to 40% of the deaths associated with this disease. Current treatment approaches include surgery, followed by radioactive iodine therapy. However, a significant proportion of locally advanced and metastatic FTC fails to concentrate iodine. Because traditional chemotherapeutic agents have not been shown to alter outcomes in this disease, novel therapeutic strategies are needed for advanced disease. Recently, a genomic rearrangement has been identified in up to 50% of FTC, involving a translocation event between chromosome regions 3p25 and 2q13. This translocation fuses the thyroid-specific transcription factor PAX8 gene with the PPARγ gene, a ubiquitously expressed transcription factor. We have confirmed that this Pax8 / PPARγ fusion gene (designated PPFP) is an oncogene, which accelerates cell growth, reduces rates of apoptosis and permits anchorage independent and contact uninhibited growth of a thyroid cell line. The action of PPFP arises, at least in part, through its activity as a dominant-negative inhibitor of the wild-type PPARγ transcription factor. Although the mechanism by which PPFP impairs PPARγ activity remains unknown at this time, it is likely to be mediated by competition for the genomic PPARγ response elements, the endogenous ligand, or various cofactors, including the Retinoid X Receptor (RXR). Consequently, modulation of PPFP activity might be possible through the use of PPARγ agonists, RXR-agonists, or specific modulators of PPFP itself. Alternatively, modulation of several down-stream regulatory pathways may become possible, as the consequences of PPARγ inhibition become better known. PPFP represents a potential novel target for the management of advanced FTC.

Original languageEnglish (US)
Pages (from-to)221-234
Number of pages14
JournalCurrent Drug Targets: Immune, Endocrine and Metabolic Disorders
Volume4
Issue number3
DOIs
StatePublished - Sep 2004

Fingerprint

Oncogene Fusion
Follicular Adenocarcinoma
Peroxisome Proliferator-Activated Receptors
Retinoid X Receptors
Iodine
Therapeutics
Thyroid Gland
Transcription Factors
Gene Fusion
Response Elements
Growth
Oncogenes
Thyroid Neoplasms
Genes
Chromosomes
Apoptosis
Ligands
Cell Line

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism
  • Immunology and Allergy

Cite this

The PAX8/PPARγ fusion oncogene as a potential therapeutic target in follicular thyroid carcinoma. / McIver, Bryan; Grebe, S. K G; Eberhardt, Norman L.

In: Current Drug Targets: Immune, Endocrine and Metabolic Disorders, Vol. 4, No. 3, 09.2004, p. 221-234.

Research output: Contribution to journalArticle

@article{357b557ddfd6406ca5fa3fca8b1a6f93,
title = "The PAX8/PPARγ fusion oncogene as a potential therapeutic target in follicular thyroid carcinoma",
abstract = "Follicular thyroid carcinoma (FTC) accounts for approximately 20{\%} of all thyroid cancers, and up to 40{\%} of the deaths associated with this disease. Current treatment approaches include surgery, followed by radioactive iodine therapy. However, a significant proportion of locally advanced and metastatic FTC fails to concentrate iodine. Because traditional chemotherapeutic agents have not been shown to alter outcomes in this disease, novel therapeutic strategies are needed for advanced disease. Recently, a genomic rearrangement has been identified in up to 50{\%} of FTC, involving a translocation event between chromosome regions 3p25 and 2q13. This translocation fuses the thyroid-specific transcription factor PAX8 gene with the PPARγ gene, a ubiquitously expressed transcription factor. We have confirmed that this Pax8 / PPARγ fusion gene (designated PPFP) is an oncogene, which accelerates cell growth, reduces rates of apoptosis and permits anchorage independent and contact uninhibited growth of a thyroid cell line. The action of PPFP arises, at least in part, through its activity as a dominant-negative inhibitor of the wild-type PPARγ transcription factor. Although the mechanism by which PPFP impairs PPARγ activity remains unknown at this time, it is likely to be mediated by competition for the genomic PPARγ response elements, the endogenous ligand, or various cofactors, including the Retinoid X Receptor (RXR). Consequently, modulation of PPFP activity might be possible through the use of PPARγ agonists, RXR-agonists, or specific modulators of PPFP itself. Alternatively, modulation of several down-stream regulatory pathways may become possible, as the consequences of PPARγ inhibition become better known. PPFP represents a potential novel target for the management of advanced FTC.",
author = "Bryan McIver and Grebe, {S. K G} and Eberhardt, {Norman L.}",
year = "2004",
month = "9",
doi = "10.2174/1568008043339802",
language = "English (US)",
volume = "4",
pages = "221--234",
journal = "Endocrine, Metabolic and Immune Disorders - Drug Targets",
issn = "1871-5303",
publisher = "Bentham Science Publishers B.V.",
number = "3",

}

TY - JOUR

T1 - The PAX8/PPARγ fusion oncogene as a potential therapeutic target in follicular thyroid carcinoma

AU - McIver, Bryan

AU - Grebe, S. K G

AU - Eberhardt, Norman L.

PY - 2004/9

Y1 - 2004/9

N2 - Follicular thyroid carcinoma (FTC) accounts for approximately 20% of all thyroid cancers, and up to 40% of the deaths associated with this disease. Current treatment approaches include surgery, followed by radioactive iodine therapy. However, a significant proportion of locally advanced and metastatic FTC fails to concentrate iodine. Because traditional chemotherapeutic agents have not been shown to alter outcomes in this disease, novel therapeutic strategies are needed for advanced disease. Recently, a genomic rearrangement has been identified in up to 50% of FTC, involving a translocation event between chromosome regions 3p25 and 2q13. This translocation fuses the thyroid-specific transcription factor PAX8 gene with the PPARγ gene, a ubiquitously expressed transcription factor. We have confirmed that this Pax8 / PPARγ fusion gene (designated PPFP) is an oncogene, which accelerates cell growth, reduces rates of apoptosis and permits anchorage independent and contact uninhibited growth of a thyroid cell line. The action of PPFP arises, at least in part, through its activity as a dominant-negative inhibitor of the wild-type PPARγ transcription factor. Although the mechanism by which PPFP impairs PPARγ activity remains unknown at this time, it is likely to be mediated by competition for the genomic PPARγ response elements, the endogenous ligand, or various cofactors, including the Retinoid X Receptor (RXR). Consequently, modulation of PPFP activity might be possible through the use of PPARγ agonists, RXR-agonists, or specific modulators of PPFP itself. Alternatively, modulation of several down-stream regulatory pathways may become possible, as the consequences of PPARγ inhibition become better known. PPFP represents a potential novel target for the management of advanced FTC.

AB - Follicular thyroid carcinoma (FTC) accounts for approximately 20% of all thyroid cancers, and up to 40% of the deaths associated with this disease. Current treatment approaches include surgery, followed by radioactive iodine therapy. However, a significant proportion of locally advanced and metastatic FTC fails to concentrate iodine. Because traditional chemotherapeutic agents have not been shown to alter outcomes in this disease, novel therapeutic strategies are needed for advanced disease. Recently, a genomic rearrangement has been identified in up to 50% of FTC, involving a translocation event between chromosome regions 3p25 and 2q13. This translocation fuses the thyroid-specific transcription factor PAX8 gene with the PPARγ gene, a ubiquitously expressed transcription factor. We have confirmed that this Pax8 / PPARγ fusion gene (designated PPFP) is an oncogene, which accelerates cell growth, reduces rates of apoptosis and permits anchorage independent and contact uninhibited growth of a thyroid cell line. The action of PPFP arises, at least in part, through its activity as a dominant-negative inhibitor of the wild-type PPARγ transcription factor. Although the mechanism by which PPFP impairs PPARγ activity remains unknown at this time, it is likely to be mediated by competition for the genomic PPARγ response elements, the endogenous ligand, or various cofactors, including the Retinoid X Receptor (RXR). Consequently, modulation of PPFP activity might be possible through the use of PPARγ agonists, RXR-agonists, or specific modulators of PPFP itself. Alternatively, modulation of several down-stream regulatory pathways may become possible, as the consequences of PPARγ inhibition become better known. PPFP represents a potential novel target for the management of advanced FTC.

UR - http://www.scopus.com/inward/record.url?scp=4444345212&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=4444345212&partnerID=8YFLogxK

U2 - 10.2174/1568008043339802

DO - 10.2174/1568008043339802

M3 - Article

VL - 4

SP - 221

EP - 234

JO - Endocrine, Metabolic and Immune Disorders - Drug Targets

JF - Endocrine, Metabolic and Immune Disorders - Drug Targets

SN - 1871-5303

IS - 3

ER -